Analysis Of Income And Expense [Abstract]

OSE Immunotherapeutics - Filing #831399

Concept	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Other revenue	—	—	0 EUR	—	—	—	—	—	0 EUR	—	—	—
Revenue	—	—	2 227 EUR	—	—	—	—	—	18 302 EUR	—	—	—
Material income and expense [abstract]
Research and development expense	—	—	17 158 EUR	—	—	—	—	—	26 893 EUR	—	—	—
Other operating income (expense)	—	—	6,000 EUR	—	—	—	—	—	84,000 EUR	—	—	—
Selling, general and administrative expense [abstract]
General and administrative expense	—	—	6 015 EUR	—	—	—	—	—	6 672 EUR	—	—	—
Expenses by nature [abstract]
Classes of employee benefits expense [abstract]
Expense from share-based payment transactions with employees	—	—	2 034 EUR	—	—	—	—	—	3 130 EUR	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	—	77,000 EUR	—	—	77,000 EUR	—	—	61,000 EUR	—	61,000 EUR	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	0 EUR	0 EUR	23 089 EUR	0 EUR	23 012 EUR	77,000 EUR	0 EUR	0 EUR	17 699 EUR	0 EUR	61,000 EUR	17 638 EUR